• Assess patient for urinary tract infection (fever, cloudy urine, frequency, urgency, pain and burning on urination) or other signs of infection at beginning of and throughout therapy.

• Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving results.

• Monitor intake and output ratios. Fluid intake should be sufficient to maintain urine output of at least 1200–1500 mL daily.

• May produce elevated serum bilirubin, creatinine, BUN, AST, and ALT.

» Monitor CBC and urinalysis periodically throughout therapy. Therapy should be discontinued if blood dyscrasias occur.